What is EchoNous?
Founded in 2016 and headquartered in Redmond, Washington, EchoNous operates at the intersection of software development and medical imaging. The company specializes in the miniaturization of ultrasound hardware, seamlessly fusing these devices with sophisticated artificial intelligence algorithms to enhance clinical decision-making. By focusing on portability and diagnostic precision, EchoNous addresses critical gaps in healthcare delivery, enabling clinicians to perform high-fidelity imaging in diverse environments, from emergency departments to remote clinical settings. Their market position is defined by a commitment to democratizing access to diagnostic tools through technological innovation and strategic partnerships.
How much funding has EchoNous raised?
EchoNous has raised a total of $159M across 4 funding rounds:
Private Equity
$35M
Private Equity
$60M
Series D
$57M
Other Financing Round
$7M
Private Equity (2017): $35M with participation from KKR
Private Equity (2021): $60M led by Kennedy Lewis Investment Management
Series D (2022): $57M supported by Kennedy Lewis Investment Management
Other Financing Round (2023): $7M, investors not publicly disclosed
Key Investors in EchoNous
KKR
KKR is a global investment firm investing across private markets in every asset class all over the world, KKR mission is to fortify companies and communities and help secure the futures of the institutions and individuals counting on us.
Kennedy Lewis Investment Management
Kennedy Lewis Investment Management is a multi-strategy private credit platform that specializes in non-sponsor lending and bespoke capital solutions for middle-market businesses in the U.S. and Western Europe.
Undisclosed Investors
What's next for EchoNous?
With the recent influx of capital, EchoNous is well-positioned to accelerate its product roadmap and expand its footprint in the global health tech market. The strategic focus will likely center on scaling the deployment of its AI-enhanced ultrasound platforms, further integrating machine learning capabilities to automate image interpretation and improve patient outcomes. As the company transitions into its next phase of growth, the emphasis will remain on strengthening its competitive moat through continuous R&D and the pursuit of new clinical applications. Investors and industry observers anticipate that this latest financing will facilitate broader commercial adoption, solidifying the company's status as a cornerstone of modern, data-driven medical diagnostics.
See full EchoNous company page
